Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Procedure: Blood sampleOther: Quality of life questionnairesProcedure: BiopsyCombination Product: Regorafenib + metronomic chemotherapy
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 174
- Registration Number
- NCT06425133
- Locations
- 🇫🇷
CHU d'Auxerre, Auxerre, France
🇫🇷Centre Hospitalier Universitaire de Besançon, Besançon, France
🇫🇷CH de Colmar, Colmar, France
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
- Conditions
- Advanced Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 136
- Registration Number
- NCT06321055
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 8
- Registration Number
- NCT06283303
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 40
- Registration Number
- NCT06283134
Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)
- Conditions
- Meningioma, Malignant
- Interventions
- Drug: Local Standard of Care
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 104
- Registration Number
- NCT06275919
- Locations
- 🇮🇹
Policlinico San Martino, Genova, Italy
🇮🇹Spedali Riuniti, Livorno, Italy
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
- Conditions
- Solid Malignant Tumors
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT06246643
- Locations
- 🇫🇷
Hôpital Beaujon - Clichy, Clichy, France
🇫🇷Hopital Claude Huriez - Lille, Lille, France
🇫🇷Hôpital Paul Brousse - Villejuif, Villejuif, France
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06200363
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
- Conditions
- Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06199973
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT06137170
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
- Conditions
- Digestive System Cancers
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 39
- Registration Number
- NCT06099821
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.